A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/07 (2006.01) A61P 9/10 (2006.01) A61P 17/02 (2006.01) A61P 41/00 (2006.01) C12N 5/00 (2006.01)
Patent
CA 2423190
The invention concerns the use of a compound of formula (I), wherein: A¿1? is the radical corresponding to D- or L-Ser; A¿2? is the radical corresponding to D- or L-Asp or Glu; A¿3? is the radical corresponding to D- or L- Lys, Arg or Orn; A¿4? is the radical corresponding to D- or L- Pro; R¿1? and R¿2? selected independently among H, C¿1?-C¿12? alkyl substituted or not;, C¿7?-C¿20? arylalkyl substituted or not, R¿4?CO, R¿4?COO, R¿4? being C¿1?-C¿12? alkyl substituted or not, C¿7?-C¿20? arylalkyl substituted or not, including among the substitutions OH, NH¿2? or COOH; X¿1? and X¿2? are peptide or pseudopeptide bonds; X¿3? is CO or CH¿2? and R¿3? is OH, NH¿2?, C¿1?-C¿12? alkoxy or NH-X¿4?-CH¿2?-Z; X¿4? is a linear or branched C¿1?-C¿12? hydrocarbon; Z is H, OH, CO¿2?H or CONH¿2?, or the corresponding tripeptides comprising the radicals A¿1?, A 2, A¿3?; and their pharmaceutically acceptable salts, for producing a medicine designed to treat pathologies likely to benefit from stimulation of angiogenesis.
La présente invention concerne l'utilisation d'un composé de formule (I), dans laquelle, A1 est le radical correspondant à D- ou L- Ser, A2 est le radical correspondant à D- ou L- Asp ou Glu, A3 est le radical correspondant à D- ou L- Lys, Arg ou Orn, A4 est le radical correspondant à D- ou L- Pro, R1 et R2 sont choisis indépendamment parmi H, C1-C12-alkyle substitué ou non, C7-C20- arylalkyle substitué ou non, R4CO ou R4COO, R4 étant C1-C12-alkyle sustitué ou non, C7-C20-arylalkyle substitué ou non, parmi les substitutions il faut citer OH, NH2 ou COOH, X1 et X2 sont des liaisons peptidiques ou pseudopeptidiques, X3 est CO ou CH2 et R3 est OH, NH2, C1-C12-alcoxy ou NH-X4-CH2-Z, X4 est un C1- C12-hydrocarbone normal ou ramifié, Z est H, OH, CO2H ou CONH2, ou bien les tripeptides correspondants comprenant les radicaux A1, A2, A3, ainsi que les sels pharmaceuticement acceptables, pour la réalisation d'un médicament destiné au traitement des pathologies pouvant bénéficier d'une stimulation de l'angiogenèse.
Bakala Joanna
Bignon Jerome
Cheviron Nathalie
Fromes Yves
Lawrence Francoise
Centre National de La Recherche Scientifique (cnrs)
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Angiogenic agents and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiogenic agents and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiogenic agents and their uses will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2081027